ROS

ROS Therapeutics is a biotechnology company focused on developing innovative cancer therapies that leverage the biology of reactive oxygen species (ROS). The company's approach involves targeting the redox imbalance in cancer cells to induce selective cell death while sparing healthy tissue. Their lead programs are primarily focused on hematologic malignancies, such as acute myeloid leukemia, and various solid tumors. By utilizing small molecule inhibitors that modulate oxidative stress pathways, ROS Therapeutics aims to overcome resistance to conventional therapies and provide new options for patients with difficult-to-treat cancers.